FYNEFTA fingolimod (as hydrochloride) 0.25 mg capsule blister pack

Ülke: Avustralya

Dil: İngilizce

Kaynak: Department of Health (Therapeutic Goods Administration)

Aktif bileşen:

fingolimod hydrochloride, Quantity: 0.28 mg (Equivalent: fingolimod, Qty 0.25 mg)

Mevcut itibaren:

Novartis Pharmaceuticals Australia Pty Ltd

Farmasötik formu:

Capsule, hard

Kompozisyon:

Excipient Ingredients: mannitol; hyprolose; hydroxypropylbetadex; magnesium stearate; Shellac; iron oxide black; propylene glycol; Gelatin; strong ammonia solution; titanium dioxide; iron oxide yellow

Uygulama yolu:

Oral

Paketteki üniteler:

7, 28

Reçete türü:

(S4) Prescription Only Medicine

Terapötik endikasyonlar:

FYNEFTA is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Ürün özeti:

Visual Identification: Ivory opaque (body and cap), size 3, with black radial imprint FTY 0.25 mg on cap and black radial band on body containing white to almost white powder; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Yetkilendirme durumu:

Registered

Yetkilendirme tarihi:

2019-04-12